BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 21, 2019
View Archived Issues
Ebola antibody cocktail is drug development model
Read More
In immunotherapy, translation's translational potential
Read More
Anxiety affects weight via BDNF, inhibitory neurons
Read More
Enrollment ongoing in phase I study of MRX-0518 plus pembrolizumab in patients with solid tumors
Read More
FDA accepts IND application for phase I/II study of AVR-RD-04 gene therapy for cystinosis
Read More
Fat and happy: combination treatment subverts tumor cell plasticity
Read More
OliX nominates OLX-10020 as a clinical candidate for geographic atrophy
Read More
Celgene enters two cancer immunotherapy collaborations
Read More
Xiamen University divulges RET inhibitors
Read More
Selvita presents adenosine A2A receptor antagonists
Read More
Aradigm releases third-party evaluation results of Apulmiq phase III trials
Read More
Preliminary phase Ib data presented for GLS-010 in patients with advanced gastrointestinal tumors
Read More
Phase I results reported for galunisertib plus SBRT in advanced hepatocellular carcinoma
Read More
Canerpaturev plus standard chemotherapy shows encouraging antitumor activity in pancreatic cancer
Read More
Phase III ANNOUNCE study of Lartruvo in soft tissue sarcoma does not meet primary endpoints
Read More
Phase III RESOLVE trial of ibrutinib in metastatic pancreatic cancer misses primary endpoint
Read More
Gilead presents phase III data for andecaliximab combined with chemotherapy
Read More
FDA approves trastuzumab biosimilar Ontruzant
Read More
Redx receives MHRA clearance to resume RXC-004 clinical trial program
Read More
First-in-human study evaluates EMB-01 in advanced/metastatic solid tumors
Read More
Syntrix opens enrollment for phase I study of SX-682 in metastatic melanoma
Read More